MGMadiwalayya Shivakantayya Ganachari

Madiwalayya Shivakantayya Ganachari

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Madiwalayya Shivakantayya Ganachari has a total of 46 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Cardiovascular Disease and Disability

    by Ramesh Bhandari, Madiwalayya S. Ganachari

  • Preliminary development and content validation of mopet–A multidomain oncology pain assessment tool for cancer care setting

    by Manjula Gudhoor, Shrinivas Sonwalkar, Maheen Khazi, Riddhi Patel, M S Ganachari

    Purpose: Cancer pain affects emotional, behavioural, social, and financial well-being beyond physical symptoms. Preliminary development and to perform content validation of a Multidomain Oncology Pain Assessment Tool incorporating physical, emotional, behavioural, sleep-related, social, and financial domains, grounded in the biopsychosocial model of pain. Methods: Mixed-method study design was used to develop and validate a pain assessment questionnaire. In the qualitative phase, focus group discussion, interviews, and expert panel reviews were conducted to generate and refine questionnaire items, ensuring cultural relevance and content validity. In the quantitative phase, healthcare professionals participated in the validation, with reliability assessed via Cronbach's alpha and content validity evaluated using S-CVI/avg scores. Results: In this preliminary content validation, the tool demonstrated excellent internal consistency (Cronbach's α = 0.84–0.94) and strong expert-rated content validity (S-CVI/avg > 0.90). The inclusion of behavioural changes, emotional withdrawal, sleep disturbances, and financial burden ensured a holistic reflection of patients’ lived experiences. Conclusions: This preliminarily validated tool provides a structured, multidimensional, patient-centred framework for assessing cancer-related pain. Further construct validity, criterion validity, and patient-level pilot testing are warranted before broader clinical deployment. Its multidimensional approach supports both pharmacological and non-pharmacological strategies, enabling more accurate and compassionate pain management. Broader multi-centre validation is recommended to strengthen its applicability in diverse clinical settings.

  • Open Access

    Fournier gangrene mimicking epididymo-funiculitis in a 63-year-old man in India: a case report

    by Mahek R. Mattikop, Meganie Velosha Fernandes, Mandati Santhosh Reddy, Pratiksha Kini, M. S. Ganachari, Ramesh S. Koujalagi

    Fournier gangrene (FG) is an uncommon but life-threatening condition characterized by rapidly spreading necrotizing fasciitis of the perianal, genital, or perineal regions and accounts for less than 0.02% of hospital admissions, with a reported fatality rate of 20% to 30%. Early diagnosis and prompt multidisciplinary management are essential for achieving optimal outcomes. A 63-year-old man presented with swelling in the right scrotal region. He underwent surgical incision and drainage followed by negative pressure wound therapy. Despite the severity of the presentation, the patient’s prognosis was favorable. This case highlights the risk of misdiagnosing FG in the outpatient setting when initial symptoms resemble benign scrotal conditions and underscores the importance of rapid intervention. The involvement of a clinical pharmacist may enhance patient care by supporting the implementation of an optimized treatment strategy for FG.

  • Design, content validation, and reliability assessment of a chemotherapy order template: Expert based content validation

    by Vivek Patil, Madiwalayya S Ganachari, Manjula Gudhoor, Alex Carvalho

    Background: Cancer remains the second leading cause of death worldwide, with nearly 10 million annual deaths. Chemotherapy, though essential, is highly complex and prone to dosing errors, interactions, and adverse effects. To improve safety and standardization, a Chemotherapy Order Template (COT) was developed based on NCCN guidelines. Objective: To design, validate, and assess the reliability of a structured Chemotherapy Order Template that supports safe, accurate, and consistent chemotherapy prescribing in oncology settings. Methods: The validation process included developing the template using NCCN (2025) guidelines, constructing a 22-item Likert-scale tool, obtaining multidisciplinary expert review, and conducting statistical testing using Pearson's correlation and Cronbach's alpha. A total of 54 experts participated. Results: The expert panel comprised 46.30% physicians, 33.33% academicians, and 9.26% clinical pharmacists. The validation tool demonstrated excellent internal consistency with an overall Cronbach's alpha of 0.99. All 22 items showed significant positive correlations (p < 0.01), confirming strong construct validity. Expert feedback led to key enhancements in the COT. Conclusion: The validated COT is a reliable and clinically relevant tool that improves safety, accuracy, and adherence to oncology guidelines in chemotherapy prescribing. Its structured design, based on expert consensus, promotes standardization, reduces medication errors, and supports coordinated, high-quality cancer care.


  • Research Ethics Committee Perspectives on the Reuse of Genetic Data: Gatekeepers of Responsible Research

    by Revana Siddappa Devarinti, Madiwalayya Shivakantayya Ganachari

    Background: Genetic research holds immense potential for advancing personalized medicine, understanding disease mechanisms, and developing targeted therapies with safe and effective outcomes. The re-use of data can accelerate scientific discovery, reduce redundancy, and enhance the value derived from research investments. However, the re-use of genetic data also raises significant ethical, legal, and social concerns. Understanding the perspectives of research ethics committee members involved in the review of clinical trial protocols is crucial for developing policies and practices that balance the benefits and risks to research participants. Objective: The primary objective of the research was to explore the knowledge, attitude, and practices of research ethics committee members on genetics and its data for re-use. Design and Method: This was a cross-sectional observation study to explore the perspectives of research ethics committee members [ n = 50] on the reuse of genetic samples and their data for future research purposes. Setting and Participants: The study was conducted in the Clinical Research Department, Karnataka, India. The research involved a diverse group of research ethics committee members, including chairpersons, Medical scientists, clinicians, legal experts, and laypersons. The present study assessed the knowledge, attitude, and practices of research ethics committee members based on their role in the Research Ethics Committee. Results: The present research KAP assessment revealed significant variability in awareness and understanding of genetic samples and their data reuse. Clinicians (90%) and medical scientists (100%) exhibited the highest levels of knowledge about the genetic data for re-use, while laypersons and legal experts reported lower levels, which might be due to their educational background ( p < 0.001). Educational background strongly influenced perspectives, with MSc-PhD holders demonstrating higher knowledge levels. The diverse levels of knowledge and varying concerns among different roles within Research Ethics Committees reflect the complex nature of ethical and legal considerations in the re-use of genetic data. Conclusion: The present research underscores the need to integrate stakeholder insights into future policy development on genetic data re-use, like ICH-GCP guidelines for clinical trials. Doing so can strengthen ethical governance, ensure participant trust, and guide the responsible reuse of genetic data in research. There are no universally accepted guidelines beyond those by ICMR (2017) and WHO (2024). Registration: Clinical trial registry in India-CTRI/2011/11/032811 dated 23.11.21


  • From reaction to reporting: Impact of pharmacovigilance in a tertiary care hospital setting at Belagavi

    by Pratiksha Kini, Mandati Santhosh Reddy, M S Ganachari

    Background: Adverse drug reactions (ADRs) pose significant risks to patient safety, particularly in tertiary care settings characterized by polypharmacy and multiple comorbidities. Monitoring and evaluating ADRs is vital to improving therapeutic outcomes and minimizing harm. Objective: This study aimed to assess the pattern, severity, predictability, seriousness, and causality of ADRs reported in a tertiary care teaching hospital in Belagavi, India. Methods: A prospective observational study was conducted on 2035 spontaneously reported ADRs collected between January and December 2024 at the Adverse Drug Reaction Monitoring Centre under the Pharmacovigilance Programme of India (PvPI). Data were analyzed using the WHO-UMC causality assessment, Hartwig and Siegel severity scale, and standard classifications for seriousness and predictability. Results: Adults (60.54%) and elderly (24.67%) were most frequently affected. Gastrointestinal disorders (23.91%) were the most commonly reported System Organ Class (SOC). Most ADRs were predictable (87.81%) and probable in causality (67.91%). Severe ADRs accounted for 15.97%. Vomiting and headache were the most reported adverse events. Antiretroviral were the most commonly implicated drug class. Conclusion: The majority of ADRs were predictable and involved widely used drug classes. Strengthening pharmacovigilance practices and implementing targeted clinical interventions are essential to prevent avoidable ADRs and improve patient safety.


  • Open Access

    Decoding adverse drug reactions in respiratory care: a prospective predictive and severity-based analysis at a tertiary care hospital in India

    by Vaishnavi V. Gaonkar, Vinay V. Shanbhag, Mandati Santhosh Reddy, M.S. Ganachari

    Adverse drug reactions (ADRs) are a major concern in healthcare, including morbidity, longer hospitalization, and increased healthcare expenses. Despite the necessity of ADR monitoring, reporting is poor, particularly in developing countries such as India. This study assessed the severity, predictability, and causality of ADRs in a tertiary care hospital’s respiratory department. A prospective observational study was conducted at KLE’s Dr. Prabhakar Kore Hospital, Belagavi, Karnataka, from September 2023 to January 2025. Patients aged 45 years and above with chronic respiratory conditions were included. ADRs were assessed using validated scales, including the World Health Organization-Uppsala Monitoring Center Scale, the Modified Hartwig and Siegel Scale, and the Predictability Assessment. Descriptive statistics were applied to analyze ADR patterns. Among the 107 patients enrolled, 63.5% were elderly and 59.8% were female. Mild ADRs accounted for 60.7% of cases, while serious responses were reported in 3.7%. Predictability analysis revealed that 77.5% of ADRs were foreseeable. Causality assessment revealed ADRs as probable (51.4%), possible (37.3%), and certain (10.2%). Drug withdrawal was the most popular intervention (55.1%). The most commonly reported ADRs were gastrointestinal disorders (33.6%), followed by respiratory (18.6%) and cardiovascular disorders (16.8%). The study highlighted the need for improved pharmacovigilance programs to reduce ADR-related hazards in respiratory patients. Improving ADR reporting methods and predictive assessments can enhance patient safety and maximize therapeutic outcomes.

  • Cardiovascular Disease and Disability

    by Ramesh Bhandari, Madiwalayya S. Ganachari


  • Clinical Trial Participant's Perspectives on Genetic Research Data Re-uses for Future Research

    by Revanasiddappa Devarinti, Madiwalayya Shivkantayya Ganachari

    Background: Clinical trial participants play a crucial role in advancing medical research, and the data generated from their participation can indeed be invaluable for future studies. However, the reuse of genetic or clinical research data comes with ethical challenges that need careful consideration. Here are some of the key ethical issues associated with the re-use of such data: Reusing data without clear informed consent raises issues of autonomy and respect for individuals' choices. Objective: The main aim of this study is to assess the understanding of individuals involved in clinical trials regarding the sharing of genetic research information. Moreover, it seeks to explore the ethical issues and benefits linked with the use of genetic research data for future research initiatives. Methods and Material: A cross-sectional observational study was applied to assess Knowledge Attitude Practices of clinical trial participants on reuse of genetic research data. Results: The majority 70% of clinical trial participants were unsure about the difficulties that may arise in future regarding the re-use of genomic data, with concerns about confidentiality being the most common. Conclusion: The present study prioritized the involvement of clinical trial participants due to their critical role in both genetic and clinical research endeavors. There is a lack of awareness and understanding regarding the re-use of genetic research data and ethical issues among the trial participants. Researchers must take measures to de-identify or anonymize data to protect participants. There is a clear need for comprehensive awareness programs and guidelines aimed at all clinical trial stakeholders. These initiatives would ensure that researchers, participants, and other involved parties are well-informed and adhere to ethical standards when utilizing genetic data for subsequent research endeavors.


  • Corn Silk (Stigma maydis) Use in Diabetes

    by Ramesh Bhandari, Raushan Kumar Chaudhary, Pukar Khanal, Madiwalayya S. Ganachari

    Isolated compounds and extracts from various medicinal plants were studied for their potential use in diabetes therapy. Corn is also known as maize, and its seeds are edible in most Asian countries. Corn silk is a long, pigmented (yellowish to reddish) hair-like structure covering the edible portion of corn. This review focuses on the molecular, cellular, and metabolic effects of corn silk (Stigma maydis) in the treatment of diabetes. The antidiabetic effect of corn silk is due to the potential candidates such as the presence of flavonoids, phenolic acids, phytosterols, carotenoids, and tannins. We discuss the effect of corn silk on cellular and molecular pathways involved in preventing and treating diabetes. Further, we cover corn silk’s toxicity and summarize other plants or parts used in diabetes treatment.